NASDAQ:AKYA Akoya Biosciences - AKYA Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akoya Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $8.18 +0.05 (+0.62%) (As of 03/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$8.14▼$8.4550-Day Range$7.60▼$12.6852-Week Range$7.20▼$16.57Volume75,444 shsAverage Volume159,118 shsMarket Capitalization$313.62 millionP/E RatioN/ADividend YieldN/APrice Target$16.17 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Akoya Biosciences MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside97.6% Upside$16.17 Price TargetShort InterestBearish4.30% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.77) to ($1.52) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.59 out of 5 starsMedical Sector842nd out of 996 stocksAnalytical Instruments Industry24th out of 29 stocks 3.5 Analyst's Opinion Consensus RatingAkoya Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.17, Akoya Biosciences has a forecasted upside of 97.6% from its current price of $8.18.Amount of Analyst CoverageAkoya Biosciences has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.30% of the float of Akoya Biosciences has been sold short.Short Interest Ratio / Days to CoverAkoya Biosciences has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in Akoya Biosciences has recently increased by 45.12%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAkoya Biosciences does not currently pay a dividend.Dividend GrowthAkoya Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AKYA. Previous Next 0.6 News and Social Media Coverage News SentimentAkoya Biosciences has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.33 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Akoya Biosciences this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added Akoya Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Akoya Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.20% of the stock of Akoya Biosciences is held by insiders.Percentage Held by InstitutionsOnly 34.61% of the stock of Akoya Biosciences is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Akoya Biosciences are expected to grow in the coming year, from ($1.77) to ($1.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Akoya Biosciences is -4.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Akoya Biosciences is -4.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAkoya Biosciences has a P/B Ratio of 5.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Akoya Biosciences (NASDAQ:AKYA) StockAkoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers Proxima, a cloud-based platform to store, analyze, and share spatial data; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.Read More Receive AKYA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akoya Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address AKYA Stock News HeadlinesMarch 24, 2023 | americanbankingnews.comAkoya Biosciences' (AKYA) "Overweight" Rating Reaffirmed at StephensMarch 21, 2023 | markets.businessinsider.comStephens Remains a Buy on Akoya Biosciences (AKYA)April 2, 2023 | Legacy Research (Affiliate) (Ad)"Prepare for Five Years of Famine"Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast.March 21, 2023 | finanznachrichten.deAkoya Biosciences, Inc.: Akoya Biosciences Announces Leadership TransitionMarch 20, 2023 | finance.yahoo.comAkoya Biosciences Announces Leadership TransitionMarch 9, 2023 | msn.comLooking Into Akoya Biosciences's Return On Capital EmployedMarch 9, 2023 | finance.yahoo.comAkoya Biosciences Full Year 2022 Earnings: EPS Misses ExpectationsMarch 8, 2023 | markets.businessinsider.comMorgan Stanley Reaffirms Their Buy Rating on Akoya Biosciences (AKYA)April 2, 2023 | Legacy Research (Affiliate) (Ad)"Prepare for Five Years of Famine"Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast.March 8, 2023 | finance.yahoo.comAkoya Biosciences, Inc. (NASDAQ:AKYA) Q4 2022 Earnings Call TranscriptMarch 7, 2023 | finance.yahoo.comQ4 2022 Akoya Biosciences Inc Earnings CallMarch 7, 2023 | finanznachrichten.deAkoya Biosciences, Inc.: Akoya Reports Record Revenue in the Fourth Quarter of 2022 and Provides Full Year 2023 Revenue GuidanceMarch 6, 2023 | msn.comAkoya Biosciences GAAP EPS of -$0.50 misses by $0.06, revenue of $21.22M beats by $0.76MMarch 6, 2023 | finance.yahoo.comAkoya Reports Record Revenue in the Fourth Quarter of 2022 and Provides Full Year 2023 Revenue GuidanceMarch 6, 2023 | finance.yahoo.comAkoya Biosciences (AKYA) Reports Q4 Loss, Tops Revenue EstimatesMarch 3, 2023 | msn.comA Preview Of Akoya Biosciences's EarningsFebruary 28, 2023 | finance.yahoo.comAkoya Biosciences Announces Appointment of Jennifer Kamocsay as General CounselFebruary 27, 2023 | finance.yahoo.comWill Akoya Biosciences (AKYA) Report Negative Earnings Next Week? What You Should KnowFebruary 6, 2023 | finance.yahoo.comAkoya to Report Fourth Quarter and Full Year 2022 Financial Results on March 6th, 2023 and Participate at Two Upcoming Investor ConferencesFebruary 1, 2023 | finance.yahoo.comAkoya Biosciences to Present First-of-its-Kind Spatial Multiomics Dataset at 2023 AGBT General MeetingJanuary 26, 2023 | seekingalpha.comAkoya Bioscience: Something Special For Investing In A Spatial Bioscience CompanyJanuary 8, 2023 | finance.yahoo.comAkoya Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2022January 6, 2023 | finance.yahoo.comAgilent and Akoya Biosciences Announce Partnership to Drive Multiplex Tissue Assay Development for Biopharma ApplicationsDecember 28, 2022 | finance.yahoo.comAkoya to Participate at 41st Annual J.P. Morgan Healthcare ConferenceDecember 15, 2022 | finance.yahoo.comAkoya Biosciences Showcases Latest Spatial Biology Innovations at Virtual Spatial DayDecember 7, 2022 | finance.yahoo.comInstitutions own 23% of Akoya Biosciences, Inc. (NASDAQ:AKYA) shares but private equity firms control 49% of the companyNovember 8, 2022 | seekingalpha.comAkoya Biosciences, Inc. (AKYA) Q3 2022 Earnings Call TranscriptSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive AKYA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akoya Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address AKYA Company Calendar Last Earnings3/06/2023Today4/02/2023Next Earnings (Estimated)5/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Analytical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AKYA CUSIPN/A CIK1711933 Webwww.akoyabio.com Phone855-896-8401FaxN/AEmployees319Year FoundedN/APrice Target and Rating Average Stock Price Forecast$16.17 High Stock Price Forecast$19.00 Low Stock Price Forecast$13.00 Forecasted Upside/Downside+97.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-70,640,000.00 Net Margins-94.36% Pretax Margin-94.20% Return on Equity-85.35% Return on Assets-39.03% Debt Debt-to-Equity Ratio1.09 Current Ratio3.03 Quick Ratio2.64 Sales & Book Value Annual Sales$74.86 million Price / Sales4.19 Cash FlowN/A Price / Cash FlowN/A Book Value$1.54 per share Price / Book5.31Miscellaneous Outstanding Shares38,340,000Free Float34,815,000Market Cap$313.62 million OptionableNot Optionable Beta1.08 Key ExecutivesMr. Brian McKelligon (Age 53)Pres, CEO & Director Comp: $566.93kDr. Garry P. Nolan Ph.D. (Age 60)Co-Founder, Independent Director & Head of the Scientific Advisory Board Comp: $22.5kMr. Joseph S. Driscoll (Age 57)Chief Financial Officer Comp: $467.98kDr. Frederic G. Pla Ph.D. (Age 63)Chief Operating Officer Comp: $445.27kDr. Nikolay Samusik Ph.D.Co-FounderDr. Yury Goltsev Ph.D.Co-FounderMr. Clifford C. HoytVP of Translational & Scientific AffairsPriyam ShahSr. Director of Bus. Devel. & Investor Relations StrategyMr. Paul GrassSr. VP of SalesMs. Marilee Moy M.B.A. (Age 63)Chief People Officer More ExecutivesKey CompetitorsBionano GenomicsNASDAQ:BNGONautilus BiotechnologyNASDAQ:NAUTCue HealthNASDAQ:HLTHSeerNASDAQ:SEERQuanterixNASDAQ:QTRXView All CompetitorsInsiders & InstitutionsParallax Volatility Advisers L.P.Sold 314,468 shares on 2/27/2023Ownership: 0.159%Alliancebernstein L.P.Bought 11,800 shares on 2/16/2023Ownership: 0.031%Morgan StanleySold 2,063 shares on 2/15/2023Ownership: 0.114%Schonfeld Strategic Advisors LLCBought 40,100 shares on 2/15/2023Ownership: 0.106%Lazard Asset Management LLCBought 3,804 shares on 2/15/2023Ownership: 0.010%View All Insider TransactionsView All Institutional Transactions AKYA Stock - Frequently Asked Questions Should I buy or sell Akoya Biosciences stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akoya Biosciences in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AKYA shares. View AKYA analyst ratings or view top-rated stocks. What is Akoya Biosciences' stock price forecast for 2023? 6 Wall Street research analysts have issued 1 year target prices for Akoya Biosciences' stock. Their AKYA share price forecasts range from $13.00 to $19.00. On average, they anticipate the company's stock price to reach $16.17 in the next year. This suggests a possible upside of 97.6% from the stock's current price. View analysts price targets for AKYA or view top-rated stocks among Wall Street analysts. How have AKYA shares performed in 2023? Akoya Biosciences' stock was trading at $9.57 at the beginning of 2023. Since then, AKYA stock has decreased by 14.5% and is now trading at $8.18. View the best growth stocks for 2023 here. Are investors shorting Akoya Biosciences? Akoya Biosciences saw a increase in short interest in March. As of March 15th, there was short interest totaling 722,700 shares, an increase of 45.1% from the February 28th total of 498,000 shares. Based on an average daily trading volume, of 131,100 shares, the short-interest ratio is currently 5.5 days. Currently, 4.3% of the shares of the stock are sold short. View Akoya Biosciences' Short Interest. When is Akoya Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023. View our AKYA earnings forecast. How were Akoya Biosciences' earnings last quarter? Akoya Biosciences, Inc. (NASDAQ:AKYA) posted its earnings results on Monday, March, 6th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.41) by $0.09. The company had revenue of $21.22 million for the quarter, compared to analysts' expectations of $20.85 million. Akoya Biosciences had a negative trailing twelve-month return on equity of 85.35% and a negative net margin of 94.36%. During the same period in the previous year, the company posted ($0.47) earnings per share. What ETFs hold Akoya Biosciences' stock? ETFs with the largest weight of Akoya Biosciences (NASDAQ:AKYA) stock in their portfolio include Principal Healthcare Innovators ETF (BTEC). What guidance has Akoya Biosciences issued on next quarter's earnings? Akoya Biosciences issued an update on its FY 2023 earnings guidance on Monday, March, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $95.00 million-$98.00 million, compared to the consensus revenue estimate of $93.08 million. When did Akoya Biosciences IPO? (AKYA) raised $125 million in an IPO on Friday, April 16th 2021. The company issued 6,600,000 shares at $18.00-$20.00 per share. J.P. Morgan, Morgan Stanley, Piper Sandler and Canaccord Genuity acted as the underwriters for the IPO. What is Akoya Biosciences' stock symbol? Akoya Biosciences trades on the NASDAQ under the ticker symbol "AKYA." How do I buy shares of Akoya Biosciences? Shares of AKYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Akoya Biosciences' stock price today? One share of AKYA stock can currently be purchased for approximately $8.18. How much money does Akoya Biosciences make? Akoya Biosciences (NASDAQ:AKYA) has a market capitalization of $313.62 million and generates $74.86 million in revenue each year. The company earns $-70,640,000.00 in net income (profit) each year or ($1.88) on an earnings per share basis. How many employees does Akoya Biosciences have? The company employs 319 workers across the globe. How can I contact Akoya Biosciences? The official website for the company is www.akoyabio.com. The company can be reached via phone at 855-896-8401 or via email at investors@akoyabio.com. This page (NASDAQ:AKYA) was last updated on 4/2/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.